5岁以下喘息儿童血液中KL―6及PAI―1变化及临床意义.docVIP

5岁以下喘息儿童血液中KL―6及PAI―1变化及临床意义 　　[摘要]目的 探?5岁以下喘息儿童血液中KL-6及PAI-1的变化及临床意义。方法 选取2015年1月～ 2016年12月在我院诊断治疗的5岁以下有喘息症状的儿童198例纳入研究对象，根据API评分标准将患儿随机分为API（哮喘预测指数）阳性组（n=104），API阴性组（n=94）。两组患儿在第1～4 周布地奈德混悬液及博利康尼雾化吸入，第4周后仅使用孟鲁司特钠口服治疗，评估记录各组患儿治疗前，治疗后4周，8周，12周时各时间点哮喘症状评分，并检测血液中KL-6及PAI-1的表达水平。结果 API阴性组中，各时间点KL-6、PAI-1的比较，差异无统计学意义（P0.05）；API阳性组随着治疗时间的延长KL-6及PAI-1的表达逐渐降低（P0.05）；两组患儿治疗前，哮喘症状评分的比较，差异无统计学意义（P0.05）；治疗后4、8、12周哮喘症状评分显著下降，与治疗前比较，差异有统计学意义（P0.05）。结论 5岁以下喘息儿童血液中KL-6及PAI-1的表达呈动态变化，与哮喘症状评分有相关性。 　　[关键词]喘息；肺泡Ⅱ型上皮细胞表面抗原；纤溶酶原激活物抑制剂-1；儿童 　　[中图分类号] R725.6 [文献标识码] A [文章编号] 1674-4721（2018）4（a）-0095-04 　　Changes and clinical significance of KL-6 and PAI-1 in the blood of children with wheeze less than 5 years old 　　GUO Cai-yun ZHANG Jin-feng▲ WEI Chu-hong YAO Long-yan SUN Yan-na 　　Department of Pediatrics，Women and Children′s Affiliated Hospital of Guangdong Medical University in Guangdong Province，Foshan 528300，China 　　[Abstract]Objective To investigate the changes and clinical significance of KL-6 and Plasminogen activator inhibitor-1（PAI-1） in children with wheezing less than 5 years old.Methods A total of 198 children under 5 years of age with wheezing symptoms diagnosed and treated in our hospital from January 2015 to December 2016 were selected and randomly divided into API positive group （n=104）and API --negative group （n=94） according to API scoring criteria.Patients in the two groups were inhaled budesonide suspension and bricanyl at 1-4 weeks，and only treated with montelukast sodium orally at 4 weeks. the asthma symptom scores were recorded before treatment，4，8 and 12 weeks after treatment，and the expression levels of KL-6 and PAI-1 in blood were detected.Results There was no significant difference between KL-6 and PAI-1 in API negative group（P0.05）.The expression of KL-6 and PAI-1 in API-positive group decreased with the treatment time（P0.05）.There was no significant difference in asthma symptom score between the two groups before treatment（P0.05）.The symptom scores of